Pharmacia & Upjohn

Fondazione Istituto Italiano Di Tecnologia

Nerviano Medical Sciences S.r.l.

University of California

Fondazione Istituto Italiano Di Technologia

Università Degli Studi Di Parma

Università Degli Studi Di Urbino "Carlo Bo"

Fondazione Per La Ricerca Sulla Fibrosi Cistica-on-Lus

Istituto Giannina Gaslini

Pharmacia & Upjohn Company

Pharmacia Corporation

Pharmacia Italia S.p.a.

Istituto Giannina Gasiini

Fondazione Per La Ricerca Sulla Fibrosi Cristica—onlus

Universita Degli Studi Di Urbino

Tiziano Bandiera

Fabio Bertozzi

Jacqueline Lansen

Daniele Piomelli

Mario Varasi

Antonino Suarato

Michele Caruso

Daniele Fancelli

Andrea Lombardi Borgia

Emanuela Caci

Loretta Ferrera

Nicoletta Pedemonte

Luis Juan Vicente Galietta

Sergio Mantegani

Rita Scarpelli

Marco Mor

Federico Sorana

Paolo Di Fruscia

Marcella Nesi

Paola Vianello

Ettore Perrone

Giorgio Tarzia

Dario Ballinari

Paolo Polucci

Manuela Villa

Mauro Angiolini

Sten Christian Orrenius

Italo Beria

Gabriella Traquandi

Carla Caccia

Enzo Brambilla

Daniela Faiardi

Jay Aaron Bertrand

Maria Gabriella Brasca

Paolo Pevarello

Steven Paul Tanis

Paolo Cozzi

Achille Panzeri

Maurizio Pulici

Francesca Quartieri

Giovanni Bottegoni

Angelo Mario Reggiani

Arturo Galvani

Chiara Pagliuca

Benedetto Grimaldi

Esther Torrente

Marina Veronesi

Andrea Nuzzi

Francesco Berti

Annalisa Fiasella

Stefano Ponzano

Alejandra Rodriguez Gimeno

Carmela Speciale

Daniela Pizzirani

Donald Bainbridge Carter

Nicola Carfagna

Danilo Mirizzi

Allen Edwin Buhl

Andrea Cavalli

Paola Gnocchi

Jurgen Moll

Jürgen Moll

Natalia Realini

Guillermo Moreno-Sanz

Juergen Moll

Gregory J Fici

Geri A Sawada

Luisa Savini

Silvia Pontis

Cesare Pellerano

Francesca Giacomina

Maurizio Meroni

Frederico Sorana

Simone Giovani

Giorgia Zaetta

Alessio De Simone

Gian Filippo Ruda

Roberto Bossi

Thomas J Raub

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Pyrazole derivatives for the treatment of cystic fibrosis

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.

Compounds and compositions for the treatment of cystic fibrosis

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities. 

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof:  It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1:  wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions

Heterocyclic derivatives for the treatment of cystic fibrosis

Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.

Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments

Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolyzing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.

Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatment

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof:  It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.

Diarylalkylamine REV-ERB antagonists and their use as medicaments

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors

Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors

The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof 

Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)

The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit.

Meta-substituted biphenyl peripherally restricted FAAH inhibitors

Growing community of inventors

Gambolo, Italy

Tiziano Bandiera